Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu Hong Granule is a Traditional Chinese Medicine (TCM) compound developed by Shuguang Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine, for the treatment of chronic heart failure (CHF) and coronary artery disease (CAD). The formula is a combination of *Cornu Cervi Pantotrichum* (Deer Antler Velvet) and *Rhodiola rosea* (or *Rhodiola wallichiana*), designed to "tonify Yang and replenish Qi" according to TCM principles. Clinically, it is used as an integrative therapy alongside standard Western medical treatments to improve left ventricular systolic function and inhibit myocardial fibrosis. Research indicates that Lu Hong Granule may exert its therapeutic effects by modulating the TGF-β1/Smad signaling pathway, thereby reducing extracellular matrix deposition and improving cardiac remodeling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lu Hong Granule.